Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Balance Sheet

Financials in millions HKD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	806.63	782.73	557.17	509.85	543.49	671.34
Trading Asset Securities	1.1	1.41	3.57	5.18	0.01	0.01
Cash & Short-Term Investments	807.73	784.14	560.74	515.03	543.49	671.35
Cash Growth	25.63%	39.84%	8.88%	-5.24%	-19.05%	11.93%
Accounts Receivable	669.32	656.55	521.06	567.31	451.24	651.93
Other Receivables	52.91	34.11	65.24	28.11	22.49	22.34
Receivables	740.97	707.62	617.02	637.24	500.06	714.24
Inventory	112.29	103.54	84.66	75.4	93.29	99.06
Restricted Cash	-	-	-	3.41	52.94	-
Other Current Assets	28.3	24.82	20.89	14.21	24.2	62.73
Total Current Assets	1,689	1,620	1,283	1,245	1,214	1,547
Property, Plant & Equipment	544.49	517.13	414.21	405.86	401.11	351.9
Long-Term Investments	10.57	14.94	46.97	40.36	27.91	56.58
Goodwill	58.44	56.55	53.95	56.02	57.15	50.9
Other Intangible Assets	977.74	959.02	884.99	828.59	793.47	603.8
Long-Term Deferred Charges	332.02	321.11	256.36	240.84	200.56	188.52
Other Long-Term Assets	3.45	1.88	28.71	10.62	7.68	64.35
Total Assets	3,616	3,491	2,983	2,828	2,712	2,863

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	9.93	11.56	7.36	10.58	10.66	4.47
Accrued Expenses	460.5	458.86	402.4	390.07	308.41	354.81
Current Portion of Long-Term Debt	94.92	65.01	69.8	235.86	105.05	153.37
Current Portion of Leases	5.07	4.09	3.27	1.7	2.57	2.55
Current Income Taxes Payable	128.17	126.49	90.52	88.97	36.98	64.91
Other Current Liabilities	85.49	100.89	135.64	83.56	97.26	109.49
Total Current Liabilities	784.08	766.91	708.98	810.74	560.92	689.59
Long-Term Debt	229.56	260.64	95.55	36.06	382.12	406.49
Long-Term Leases	19.44	17.16	18.43	20.4	-	2.78
Long-Term Deferred Tax Liabilities	33.64	32.97	36.37	36.58	37.99	30.31
Total Liabilities	1,067	1,078	859.33	903.78	981.03	1,129

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	56.7	56.7	56.71	56.76	57.16	57.56
Additional Paid-In Capital	73.28	73.28	73.28	73.28	73.29	73.29
Retained Earnings	2,521	2,450	2,217	1,936	1,711	1,554
Comprehensive Income & Other	-99.17	-166.98	-223	-141.93	-109.83	49.17
Shareholders' Equity	2,549	2,413	2,124	1,924	1,731	1,734
Total Liabilities & Equity	3,616	3,491	2,983	2,828	2,712	2,863

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	348.99	346.9	187.04	294.02	489.73	565.19
Net Cash (Debt)	458.74	437.24	373.7	221	53.76	106.17
Net Cash Growth	30.44%	17.00%	69.09%	311.11%	-49.36%	186.75%
Net Cash Per Share	0.81	0.77	0.64	0.37	0.09	0.18
Filing Date Shares Outstanding	566	567.01	567.13	567.59	571.6	575.56
Total Common Shares Outstanding	566	567.01	567.13	567.59	571.6	575.56
Working Capital	905.2	853.22	574.32	434.53	653.06	857.81
Book Value Per Share	4.50	4.26	3.74	3.39	3.03	3.01
Tangible Book Value	1,513	1,398	1,185	1,039	880.75	1,080
Tangible Book Value Per Share	2.67	2.46	2.09	1.83	1.54	1.88
Buildings	134.06	128.88	114.2	116.63	117.71	127.06
Machinery	370.48	357.4	289.58	284.4	287.48	166.53
Construction In Progress	252.2	219.27	158.86	140.49	126.38	173.95

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 27, 2026

Data Sources Report a data error